PharmaCyte Biotech (PMCB) Institutional Ownership → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free PMCB Stock Alerts $2.11 -0.01 (-0.47%) (As of 04/26/2024 ET) Add Compare Share Share OwnershipStock AnalysisChartCompetitorsEarningsFinancialsOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsOptions ChainOwnershipSEC FilingsShort InterestSocial Media Institutional Ownership Changes (13F Filings) for PharmaCyte Biotech (NASDAQ:PMCB)CurrentInstitutional OwnershipPercentage34.24%Number ofInstitutional Buyers(last 12 months)4TotalInstitutional Inflows(last 12 months)$605.00KNumber ofInstitutional Sellers(last 12 months)2TotalInstitutional Outflows(last 12 months)$2.42M Get PMCB Insider Trade Alerts Want to know when executives and insiders are buying or selling PharmaCyte Biotech stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data PMCB Institutional Buying and Selling by Quarter Ad Investing DailyThey say it’s ‘unstoppable’ – How I made 43,509% Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. PharmaCyte Biotech Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/14/2024K2 Principal Fund L.P.304,613$655K0.1%+17.8%3.534% 11/15/2023Sabby Management LLC97,124$204K0.1%N/A1.106% 11/13/2023K2 Principal Fund L.P.258,481$543K0.1%+67.6%2.944% 10/17/2023Equitec Proprietary Markets LLC82,727$174K0.0%+34.7%0.942% 8/15/2023K2 Principal Fund L.P.154,232$441K0.1%-78.7%1.757% 8/14/2023CSS LLC IL13,186$38K0.0%N/A0.150% 7/12/2023Equitec Proprietary Markets LLC61,415$176K0.1%-81.4%0.366% 5/11/2023K2 Principal Fund L.P.723,271$2.06M0.3%-1.2%4.146% 2/10/2023K2 Principal Fund L.P.732,105$2.15M0.3%+19.8%3.909% 1/10/2023FNY Investment Advisers LLC31,100$90K0.1%N/A0.166% 10/26/2022IQ EQ FUND MANAGEMENT IRELAND Ltd38,771$93K0.0%N/A0.187% 10/11/2022Equitec Proprietary Markets LLC330,694$794K0.2%-3.6%1.594% 10/4/2022Csenge Advisory Group200,104$480K0.0%N/A0.964% 7/18/2022Equitec Proprietary Markets LLC342,994$768K0.2%+10.9%1.655% 5/17/2022Shay Capital LLC944,666$2.17M0.3%+42.6%4.559% 4/25/2022FNY Investment Advisers LLC59,066$135K0.1%N/A0.285% 4/22/2022Equitec Proprietary Markets LLC309,294$711K0.2%+19.6%1.493% 2/15/2022Shay Capital LLC662,337$1.66M0.3%+4,434.7%3.197% 1/31/2022Equitec Proprietary Markets LLC258,694$647K0.1%N/A1.249% 11/16/2021Schonfeld Strategic Advisors LLC88,200$280K0.0%N/A0.426% 11/12/2021NorthRock Partners LLC37,164$118K0.0%N/A0.179% (Data available from 1/1/2016 forward) PMCB Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of PMCB shares? During the previous two years, the following institutional investors and hedge funds held shares of PharmaCyte Biotech shares: Shay Capital LLC ($2.17M), K2 Principal Fund L.P. ($655K), Csenge Advisory Group ($480K), Sabby Management LLC ($204K), Equitec Proprietary Markets LLC ($174K), IQ EQ FUND MANAGEMENT IRELAND Ltd ($93K), and FNY Investment Advisers LLC ($90K).Learn more on PMCB's institutional investors. What percentage of PharmaCyte Biotech stock is owned by institutional investors? 34.24% of PharmaCyte Biotech stock is owned by institutional investors. Learn more on PMCB's institutional investor holdings. Which institutional investors have been buying PharmaCyte Biotech stock? The following institutional investors have purchased PharmaCyte Biotech stock in the last 24 months: Shay Capital LLC ($282.33K), K2 Principal Fund L.P. ($271.32K), Csenge Advisory Group ($200.10K), Sabby Management LLC ($97.12K), Equitec Proprietary Markets LLC ($55.01K), IQ EQ FUND MANAGEMENT IRELAND Ltd ($38.77K), and FNY Investment Advisers LLC ($31.10K). How much institutional buying is happening at PharmaCyte Biotech? Institutional investors have bought a total of 988,949 shares in the last 24 months. This purchase volume represents approximately $2.35M in transactions. Which PharmaCyte Biotech major shareholders have been selling company stock? The following institutional investors have sold PharmaCyte Biotech stock in the last 24 months: K2 Principal Fund L.P. ($577.87K), and Equitec Proprietary Markets LLC ($281.58K). How much institutional selling is happening at PharmaCyte Biotech? Institutional investors have sold a total of 859,452 shares in the last 24 months. This volume of shares sold represents approximately $2.45M in transactions. Related Companies: SRZN Institutional Ownership APTO Institutional Ownership EVAX Institutional Ownership IKT Institutional Ownership SNTI Institutional Ownership COEP Institutional Ownership GENE Institutional Ownership NKGN Institutional Ownership BCDA Institutional Ownership PLUR Institutional Ownership This page (NASDAQ:PMCB) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithProtect Your Bank Account Before It’s Too LateWeiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PharmaCyte Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
